Similar articles

• DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

  Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. Terrazzino S, et al. Pharmacogenomics. 2013 Aug;14(11):1255-72. doi: 10.2217/pgs.13.116. Pharmacogenomics. 2013. PMID: 23930673
• 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.

  Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W, Kładny J, Gziut K, Bielicki D, Ciechanowicz A. Sulzyc-Bielicka V, et al. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42. Pharmacol Rep. 2008. PMID: 18443386
• Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

  Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, Gelderblom H. Lunenburg CATC, et al. Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Eur J Cancer. 2016. PMID: 26716401 Review.
• Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.

  Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH. Bosch TM, et al. Mol Diagn Ther. 2007;11(2):105-8. doi: 10.1007/BF03256229. Mol Diagn Ther. 2007. PMID: 17397246
• Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.

  Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F. Uzunkoy A, et al. Anticancer Res. 2007 Nov-Dec;27(6B):3899-902. Anticancer Res. 2007. PMID: 18225548